Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q24632064)
Watch
English
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
scientific article
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
23020132
retrieved
13 November 2016
title
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
(English)
1 reference
stated in
PubMed
PubMed ID
23020132
retrieved
13 November 2016
main subject
melanoma
0 references
author
Igor Puzanov
series ordinal
17
0 references
Adil Daud
object named as
Adil Daud
series ordinal
3
0 references
Georgina V. Long
object named as
Georgina V Long
series ordinal
16
0 references
Richard F. Kefford
object named as
Richard F Kefford
series ordinal
5
0 references
Keith Flaherty
series ordinal
1
object named as
Keith T Flaherty
0 references
Jeffrey S Weber
series ordinal
26
object named as
Jeffrey Weber
0 references
Jeffrey A Sosman
series ordinal
6
object named as
Jeffrey Sosman
0 references
Nageatte Ibrahim
series ordinal
10
object named as
Nageatte Ibrahim
0 references
Peter F Lebowitz
series ordinal
18
object named as
Peter Lebowitz
0 references
Omid Hamid
series ordinal
7
object named as
Omid Hamid
0 references
Lynn Schuchter
series ordinal
8
object named as
Lynn Schuchter
0 references
Jonathan Cebon
series ordinal
9
object named as
Jonathan Cebon
0 references
Ragini R Kudchadkar
series ordinal
11
object named as
Ragini Kudchadkar
0 references
Howard A Burris
series ordinal
12
object named as
Howard A Burris
0 references
Gerald Falchook
series ordinal
13
object named as
Gerald Falchook
0 references
Alain P Algazi
series ordinal
14
object named as
Alain Algazi
0 references
Shonda Little
series ordinal
20
object named as
Shonda Little
0 references
Daniele Ouellet
series ordinal
23
object named as
Daniele Ouellet
0 references
Kiran D Patel
series ordinal
25
object named as
Kiran Patel
0 references
author name string
Jeffery R Infante
series ordinal
2
0 references
Rene Gonzalez
series ordinal
4
0 references
Karl Lewis
series ordinal
15
0 references
Ajay Singh
series ordinal
19
0 references
Peng Sun
series ordinal
21
0 references
Alicia Allred
series ordinal
22
0 references
Kevin B Kim
series ordinal
24
0 references
language of work or name
English
0 references
publication date
November 2012
0 references
published in
The New England Journal of Medicine
0 references
volume
367
0 references
issue
18
0 references
page(s)
1694-703
0 references
on focus list of Wikimedia project
ScienceSource
0 references
cites work
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
MEK1 mutations confer resistance to MEK and B-RAF inhibition
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
Improved survival with MEK inhibition in BRAF-mutated melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
7 April 2017
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
27 September 2017
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
27 September 2017
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
27 September 2017
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
27 September 2017
The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549295
retrieved
30 May 2018
Identifiers
DOI
10.1056/NEJMOA1210093
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
51585
OpenCitations bibliographic resource ID
51585
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
51585
PMCID
3549295
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
51585
PubMed ID
23020132
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
51585
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
